Moreover, intestinal FGF15 expression is decreased in intestinal NPC1L1-deficient mice [43], and whether EZE therapy will inhibit the FGF15/19-FGFR4 axis and hence promote the risk of CGD remains to be verified. Here, FGFR4 is linked to chronic granulomatous disease.